Atrial Fibrillation (AF)SNAPSNCT07407790
The Southern-Norway Post-Stroke Atrial Fibrillation Study
A study testing Patch ECG in people with Atrial Fibrillation (AF) and Atrial Fibrillation (Prevention of Stroke), run by Sorlandet Hospital HF at 1 site in Norway.
Trial summary
This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Ischemic Stroke
- What is being tested?
- Patch ECG
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 450 participants
- Where
- 1 siteNorway
- Study dates
- 10 Jan 2026to Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.
- Initial evaluation of CT and/or CT angiography and/or MRI supports a diagnosis of TIA or ischemic stroke.
- Available smartphone and access to the ECG247-app to be able to participate in the study.
- Estimated life span of >6 month
- Permanent address in Norway
- Informed Consent, Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.
Who cannot join
- Participants are excluded from the study if any of the following criteria apply:
- Medical Conditions
- Known AF or atrial flutter prior to inclusion
- Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).
- Implanted pacemaker, ICD or loop-recorder
- >70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound
- Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.
The study will include approximately 450 adults who have had a stroke or a transient "mini-stroke" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:
Read more
- Group 1 (Intervention): Participants wear the "ECG247 Smart Heart Sensor." This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.
- Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a "Holter monitor" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.
The main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.
Read the detailed description
Background and Rationale Atrial fibrillation (AF) is a major risk factor for ischemic stroke, yet it often goes undetected due to its paroxysmal (intermittent) nature. While guidelines recommend prolonged heart rhythm screening after a stroke of undetermined cause, standard hospital practice often relies on short-term telemetry and ambulatory Holter monitoring. These standard methods can be limited by device availability, bulkiness, and short monitoring duration (typically 24-48 hours), potentially leading to under-diagnosis of AF.
This study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care.
Study Design This is a prospective, randomized, parallel-group, open-label (no masking) study conducted at a single stroke center. Approximately 450 eligible patients will be enrolled.
Recruitment and Stratification Patients admitted with ischemic stroke or transient ischemic attack (TIA) within the last two weeks are screened for eligibility, aiming for inclusion within 48 hours of admission. Participants are randomized in a 1:1 ratio to either the intervention arm or the standard care arm. Randomization is stratified by age into three groups: 18-64 years, 65-74 years, and ≥75 years.
Intervention Arm (ECG247 Smart Heart Sensor) Patients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital.
- Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis.
- Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge.
- Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF >30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes.
- Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted.
Control Arm (Standard Care) Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.
- In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority.
- Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist.
- Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist.
Biomarker Analysis Blood samples will be collected from all participants to analyze N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The study will assess the association between NT-proBNP levels and the detection of silent AF to evaluate its potential for risk stratification.
Outcomes and Follow-up
- Primary Outcome: The detection rate of AF (defined as episodes ≥30 seconds).
- Secondary Outcomes: Time to AF detection, time to initiation of anticoagulation therapy, total monitoring duration, and health economics.
- User Experience: Patients in the intervention group will complete Patient Reported Experience Measures (PREMs) regarding usability and satisfaction.
- Long-term Follow-up: Participants will be followed for up to 12 months to assess clinical endpoints, including secondary stroke, TIA, and major bleeding.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Ischemic Stroke, Secondary Prevention, Arrhythmia Atrial
- Being tested
- Patch ECG, Standard Care (in control arm)
- Keywords
- stroke, atrial fibrillation, anticoagulation
- Medical subject headings
- Atrial Fibrillation, Ischemic Stroke, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patch ECGDevice
This study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care.
Standard Care (in control arm)Device
Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Arm (ECG247 Smart Heart Sensor) | Experimental | Patients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital.
* Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis.
* Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge.
* Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF >30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes.
* Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted. Receives: Device: Patch ECG |
| Control Arm (Standard Care) | Other | Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.
* In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority.
* Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist.
* Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist. Receives: Device: Standard Care (in control arm) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection rate of atrial fibrillation
The detection rate of AF (defined as episodes ≥30 seconds). Analysis will be performed on an intention-to-treat basis, and AF detection will be primarily assessed for its non-inferiority and secondarily for difference in proportions. An interim analysis for efficacy measures will be performed using the O'Brien-Flemming correction for the primary endpoint AF detection rate after 72 and 144 participants in each arm.
Measured: From enrollment to the end of heart rate monitoring. Will also be registered on follow up after 12 months.
Time from enrollment to treatment initiation with anticoagulant medicine
Days from enrollment until AF detection results in change of prophylactic treatment, defined as prescribed anticoagulant medication collected by the patient, retrieved from e-prescription data accessed through the Summary Care Record (Kjernejournal).
Measured: From enrollment until end of follow up (12 months after enrollment).
Time from enrollment to detection of first AF episode
Time to detection of first episode of atrial fibrillation after hospital admission
Measured: From enrollment up to 1 year
Total duration of heart rate monitoring
Total duration of heart rate monitoring, also including an assessment of device signal quality for assessment
Measured: From enrollment up to 1 year
Numbers of participants with secondary stroke/TIA and/or major bleeding
Assessing secondary stroke and major bleeding at 1 year of follow-up
Measured: From enrollment to one-year follow up, assessed at 1-year follow up.
Secondary outcomes (7)
Explore the practical utility in regards to validity of results of AF screening after a stroke with a patch ECG
Inter-rater validity of ECG results between the ECG247 algorithm, cardiologists and neurologists
Measured: After 1 year of recruitment
Explore the practical utility of time consumed using AF screening after a stroke with a patch ECG
A suitable number of observations will be performed to evaluate the time needed to complete the patch ECG attachment and inform the patient, interpret the results and follow-up of results
Measured: After 1 year of recruitment
Explore the practical utility and reliability of AF screening after a stroke with a patch ECG
Reliability of the monitoring device in crude versus interpretable monitoring duration in hours. Reliability will be assessed by the study personnel when creating the patch ECG result record. The whole pulse rate strip will be analyzed to identify periods of 1>h with a lack of signal or reduced signal quality. The total monitoring duration registered by the algorithm in hours versus manual interpretation with readable signal in hours will be evaluated as a percentage: Useable monitoring time/Total monitoring time x 100% = Percentage of useful monitoring.
Measured: Assessed at 1 year after enrollment start
Explore the practical utility and patient satisfaction of AF screening after a stroke with a patch ECG
Patient Reported Experience Measures (PREMs) to all patients in interventional arm within a month of discharge and within 1 month of Holter completion for control arm, registration of technical problems, allergic reactions to patch, photo of patch placement and registration of patients not considered eligible to the study due to lack of smartphone and other causes not listed in the exclusion/inclusion criteria. PREMS will be reported by a 7 point Likert scale, with higher values indicating a high level of satisfaction.
Measured: Through study completion
Diagnostic quality of in-house patch ECG compared to telemetry
Sensitivity and specificity of AF detection in patch ECG compared to concomitant telemetry.
Assessment of detection of other dangerous arrhythmias in patch ECG compared to telemetry.
Quality of signal from telemetry compared to patch ECG. In the subgroup of patients where patch ECG and telemetry are worn simultaneously, the results of both methods will be cross-validated against each other
Measured: From start of enrollment until discharge of last included patient
Cost effectiveness of patch ECG compared to standard care
Cost-effectiveness analysis of patch ECG and standard care with the endpoint being reduced secondary stroke
Measured: From enrollment until end of follow up.
Assess predictors of silent AF
Association between clinical, radiological and laboratory factors (including) NT-pro-BNP level and AF NT-proBNP will be assessed upon inclusion and can be analyzed from blood samples drawn on day 1 after admission.
MRI results Echocardiography results CHADSVASC, age, gender, medication used, previous diseases, BMI
Measured: From enrollment until end of patient follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2026
- Study start10 Jan 2026
- Primary completionDec 2028 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective, randomized, parallel-group, open-label (no masking) screening study.
- Masking
- None (open label)
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sorlandet Hospital HF
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07407790
- Sponsor's protocol ID
- REKID 931942
- Acronym
- SNAPS
- Status last verified
- Dec 2025
- First submitted
- 25 Jan 2026
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Currently undecided regarding the sharing of IPD. No established formal cooperation agreements with external research groups to date. Any future decision to share data will depend on the establishment of such collaboration agreements in adherence to data protection regulations.
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Southern-Norway Post-Stroke Atrial Fibrillation Study
- ClinicalTrials.gov ID
- NCT07407790
- Acronym / sponsor ID
- SNAPS / REKID 931942
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Ischemic Stroke, Secondary Prevention, Arrhythmia Atrial
- Keywords
- stroke, atrial fibrillation, anticoagulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Sorlandet Hospital HFOther government
- Study start
- 10 Jan 2026 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 12 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.
The study will include approximately 450 adults who have had a stroke or a transient "mini-stroke" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:
- Group 1 (Intervention): Participants wear the "ECG247 Smart Heart Sensor." This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.
- Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a "Holter monitor" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.
The main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.
Detailed description
Background and Rationale Atrial fibrillation (AF) is a major risk factor for ischemic stroke, yet it often goes undetected due to its paroxysmal (intermittent) nature. While guidelines recommend prolonged heart rhythm screening after a stroke of undetermined cause, standard hospital practice often relies on short-term telemetry and ambulatory Holter monitoring. These standard methods can be limited by device availability, bulkiness, and short monitoring duration (typically 24-48 hours), potentially leading to under-diagnosis of AF.
This study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care.
Study Design This is a prospective, randomized, parallel-group, open-label (no masking) study conducted at a single stroke center. Approximately 450 eligible patients will be enrolled.
Recruitment and Stratification Patients admitted with ischemic stroke or transient ischemic attack (TIA) within the last two weeks are screened for eligibility, aiming for inclusion within 48 hours of admission. Participants are randomized in a 1:1 ratio to either the intervention arm or the standard care arm. Randomization is stratified by age into three groups: 18-64 years, 65-74 years, and ≥75 years.
Intervention Arm (ECG247 Smart Heart Sensor) Patients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital.
- Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis.
- Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge.
- Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF >30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes.
- Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted.
Control Arm (Standard Care) Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines.
- In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority.
- Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist.
- Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist.
Biomarker Analysis Blood samples will be collected from all participants to analyze N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The study will assess the association between NT-proBNP levels and the detection of silent AF to evaluate its potential for risk stratification.
Outcomes and Follow-up
- Primary Outcome: The detection rate of AF (defined as episodes ≥30 seconds).
- Secondary Outcomes: Time to AF detection, time to initiation of anticoagulation therapy, total monitoring duration, and health economics.
- User Experience: Patients in the intervention group will complete Patient Reported Experience Measures (PREMs) regarding usability and satisfaction.
- Long-term Follow-up: Participants will be followed for up to 12 months to assess clinical endpoints, including secondary stroke, TIA, and major bleeding.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a prospective, randomized, parallel-group, open-label (no masking) screening study.
| Arm | Type | Receives |
|---|---|---|
| Intervention Arm (ECG247 Smart Heart Sensor) | Experimental | Device: Patch ECGPatients in this group will have the ECG247 patch applied to the anterior chest wall while in the hospital. * Device: The ECG247 is a wireless, water-resistant patch sensor that connects to a dedicated smartphone application via Bluetooth. It transmits data to a secure cloud service for analysis. * Duration: The device is worn continuously for up to 14 days. Monitoring begins in-hospital and continues after discharge. * Analysis: The system utilizes an algorithm to detect arrhythmia. Episodes of AF >30 seconds are considered positive findings. Study personnel and physicians verify algorithm-detected episodes. * Concurrent Care: These patients also receive standard in-house telemetry per hospital protocol while admitted. |
| Control Arm (Standard Care) | Other | Device: Standard Care (in control arm)Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines. * In-hospital: Monitoring via continuous telemetry or intermittent ECGs based on availability and clinical priority. * Ambulatory: Upon discharge, patients are referred for ambulatory Holter monitoring. The duration is typically 24-48 hours as decided by the treating cardiologist. * Analysis: Holter recordings are analyzed by trained technicians and reviewed by a cardiologist. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.
- Initial evaluation of CT and/or CT angiography and/or MRI supports a diagnosis of TIA or ischemic stroke.
- Available smartphone and access to the ECG247-app to be able to participate in the study.
- Estimated life span of >6 month
- Permanent address in Norway
Key exclusion criteria (7 listed)
- Medical Conditions
- Known AF or atrial flutter prior to inclusion
- Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).
- Implanted pacemaker, ICD or loop-recorder
- >70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patch ECGThis study aims to evaluate the clinical utility and cost-effectiveness of a novel, continuous patch ECG system (ECG247) initiated in the hospital setting compared to standard care. | Device | Intervention Arm (ECG247 Smart Heart Sensor) |
| Standard Care (in control arm)Patients in this group receive standard heart rhythm monitoring according to current hospital guidelines. | Device | Control Arm (Standard Care) |
Primary outcome
Detection rate of atrial fibrillation
Time frame: From enrollment to the end of heart rate monitoring. Will also be registered on follow up after 12 months.
The detection rate of AF (defined as episodes ≥30 seconds). Analysis will be performed on an intention-to-treat basis, and AF detection will be primarily assessed for its non-inferiority and secondarily for difference in proportions. An interim analysis for efficacy measures will be performed using the O'Brien-Flemming correction for the primary endpoint AF detection rate after 72 and 144 participants in each arm.
Time from enrollment to treatment initiation with anticoagulant medicine
Time frame: From enrollment until end of follow up (12 months after enrollment).
Days from enrollment until AF detection results in change of prophylactic treatment, defined as prescribed anticoagulant medication collected by the patient, retrieved from e-prescription data accessed through the Summary Care Record (Kjernejournal).
Time from enrollment to detection of first AF episode
Time frame: From enrollment up to 1 year
Time to detection of first episode of atrial fibrillation after hospital admission
Total duration of heart rate monitoring
Time frame: From enrollment up to 1 year
Total duration of heart rate monitoring, also including an assessment of device signal quality for assessment
Numbers of participants with secondary stroke/TIA and/or major bleeding
Time frame: From enrollment to one-year follow up, assessed at 1-year follow up.
Assessing secondary stroke and major bleeding at 1 year of follow-up
7 secondary outcomes
Explore the practical utility in regards to validity of results of AF screening after a stroke with a patch ECG
Time frame: After 1 year of recruitment
Explore the practical utility of time consumed using AF screening after a stroke with a patch ECG
Time frame: After 1 year of recruitment
Explore the practical utility and reliability of AF screening after a stroke with a patch ECG
Time frame: Assessed at 1 year after enrollment start
Explore the practical utility and patient satisfaction of AF screening after a stroke with a patch ECG
Time frame: Through study completion
Diagnostic quality of in-house patch ECG compared to telemetry
Time frame: From start of enrollment until discharge of last included patient
Cost effectiveness of patch ECG compared to standard care
Time frame: From enrollment until end of follow up.
Assess predictors of silent AF
Time frame: From enrollment until end of patient follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: Undecided. Currently undecided regarding the sharing of IPD. No established formal cooperation agreements with external research groups to date. Any future decision to share data will depend on the establishment of such collaboration agreements in adherence to data protection regulations.
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patch ECG in people with Atrial Fibrillation (AF) and Atrial Fibrillation (Prevention of Stroke), run by Sorlandet Hospital HF at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Halvor Oeygarden, PhD (+4747621336, halvor.oygarden@sshf.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection rate of atrial fibrillation (time frame: From enrollment to the end of heart rate monitoring. Will also be registered on follow up after 12 months.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.